SGLT-2 Inhibitors for Diabetes | Right Decisions

Announcements and latest updates

Welcome to the Right Decision Service (RDS) newsletter for August 2024.

Contingency planning for RDS outages

Following the recent RDS outages, Tactuum and the RDS team have been reviewing the learning from these incidents. We are committed to doing all we can to ensure a positive outcome by strengthening the RDS to make it fully robust and clinically resilient for the future.

We would like to invite you to a webinar on 26^th September 3-4 pm on national and local contingency planning for future RDS outages. Tactuum and the RDS team will speak about our business continuity plans and the national contingency arrangements we are putting in place. This will also be a space to share local contingency plans, ideas and existing good practice. We would also like to gather your views on who we should send communications to in the event of future outages.

I have sent a meeting request for this date to all editors – please accept or decline to indicate attendance, and please forward on to relevant contacts. You can also contact Olivia.graham@nhs.scot directly to register your interest in participating.

2.National IV fluid prescribing calculator

This UK CA marked calculator is now live at https://righdecisions.scot.nhs.uk/ivfluids . It has been developed by a multiprofessional steering group of leads in IV fluids management, as part of the wider Modernising Patient Pathways Programme within the Centre for Sustainable Delivery. It aims to address a known cause of clinical error in hospital settings, and we hope it will be especially useful to the new junior doctors who started in August.

Please do spread the word about this new calculator and get in touch with any questions.

New toolkits

The following toolkits are now live;

Gender identity healthcare: adults and young people standards. (https://rightdecisions.scot.nhs.uk/genderidentity ) Note that this toolkit includes self-evaluation forms for each standard. A Scottish Government launch of these standards, together with the toolkit and NES educational resources, is planned for 3^rd September.
Care Inspectorate staffing method framework.
Vascular surgery pathways from the Modernising Patient Pathways Programme within the Centre for Sustainable Healthcare Delivery.

Updated guidance on current and future Medical Device Regulations

We have updated and simplified this guidance within our standard operating procedures. We have clarified the guidance on how to determine whether an RDS tool is a medical device, and have provided an interactive powerpoint slideset to steer you through the process.

Guide to six stages of RDS toolkit development

We have developed a guide to support editors and toolkit leads through the process of scoping, designing, delivering, quality assuring and implementing a new RDS toolkit. We hope this will help in project planning and in building shared understanding of responsibilities throughout the full development process. The guide emphasises that the project does not end with launch of the new toolkit. Implementation, communication and evaluation are ongoing activities throughout the lifetime of the toolkit.

Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

Thursday 5 September 1-2 pm
Wednesday 24 September 4-5 pm
Friday 27 September 12-1 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

7 Evaluation projects

Dr Stephen Biggart from NHS Lothian has kindly shared with us the results of a recent survey of use of the Edinburgh Royal Infirmary of Edinburgh Anaesthesia toolkit. This shows that the majority of consultants are using it weekly or monthly, mainly to access clinical protocols, with a secondary purpose being education and training purposes. They tend to find information by navigating by specialty rather than keyword searching, and had some useful recommendations for future development, such as access to quick reference guidance.

We’d really appreciate you sharing any other local evaluations of RDS in this way – it all helps to build the evidence base for impact.

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

NHS Borders

Borders Diabetes team

Please contact the service for a copy of this information in another language, Braille, large print or BSL DVD

"Information given on this site is not meant to take the place of a talk with your doctor or health worker."

What are SGLT-2 inhibitors?

Sodium glucose co-transporter 2 (SGLT-2) inhibitors are tablets used to treat Type 2 diabetes. They work in the kidneys so that you pass extra glucose (sugar) in your urine.

Examples of SGLT-2 tablets are:

Empagliflozin (jardiance)
Dapagliflozin (forxiga)
Canagliflozin (ivokana)

What are the possible benefits?

better control of Type 2 diabetes - SGLT-2 inhibitors help to lower blood glucose (sugar)
weight loss
better control of blood pressure
living longer, improved survival in heart and kidney disease

What are the possible side effects?

increased risk of genital infections such as thrush or urinary tract infections (UTIs). Rarely, infections can be
very serious and require hospital treatment you must seek medical attention urgently if you notice
swelling, redness or tenderness in the genitals or the skin between the genitals and the rectum (back passage)
or have a fever or feel unwell increased urination, thirst and tendency to become dehydrated
nausea
diabetic ketoacidosis (DKA)
possible increased risk of needing a toe amputation

please tell your diabetes specialist if you have had problems with foot ulcers or operations to your feet

Diabetic Ketoacidosis (DKA)

DKA is a condition where the body does not have enough insulin and acid levels in the blood get too high
it is rare in Type 2 diabetes, but serious

What can you do to reduce DKA risk?

stop taking your SGLT-2 inhibitor:

3 days before an operation
if you are unwell with an infection or illness, or are unable to eat with nausea or vomiting
if you get symptoms of DKA (unwell with nausea and vomiting, abdominal pain, rapid breathing) then see
an emergency doctor, and tell them that you are on this medication and are worried about diabetic ketoacidosis (DKA)

check with a doctor before starting this medication again

Next review date: 31/07/2024

Author(s): Williamson R.

Author email(s): rachel.Williamson@borders.scot.nhs.uk.

Approved By: Clinical Governance & Quality

Reviewer name(s): Williamson R.